In the April 20th issue of Nature magazine, an article entitled "Pharmaco-metabonomic phenotyping and personalized drug treatment" seems to be another proof that the Carbon Based System of interpreting lab data was right after all.

The authors state that drugs affect laboratory animals with similar genetics differently based upon "variation in metabolic phenotype, which is influenced not only by genotype but also by environmental factors such as nutritional status, the gut microbiota, age, disease and the co- or ore-administration of other drugs." Of course, being funded by Pfizer, they are myopically looking at drug interventions (although in the last line they do mention dietary challenges) but since Carbon Based was started back in 1994 we believed that this form of "metabonomic phenotyping" was the wave of the future over even genetics which the authors admit that "it seems unlikely that personalized drug therapy will be enabled for a wide range of major diseases using genomic knowledge alone." They used many of the same markers as those found in Urinary Organic Acid testing which we use regularly.

The authors also comment that “metabolite profiling of fluids other than urine, such as blood and fecal extracts, should also provide additional information.”, which we find interesting as this is exactly what Carbon Based Corporation has been doing for years. We are the first ones to combine test results from blood, urine and fecal testing and we are the only ones to do that from multiple labs. Clayton et al further states that “…we envisage that similar methodology could also be applied to predicting individual responses to broader medical, dietary, microbiological or physiological challenges.” Dr. Clayton and his group don’t need to look to the future as Carbon Based Corporation has already been doing this for over 12 years.

Mark Schauss

www.MarkSchauss.com